Clear Harbor Asset Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 52.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 47,882 shares of the biopharmaceutical company’s stock after buying an additional 16,555 shares during the period. Clear Harbor Asset Management LLC’s holdings in Gilead Sciences were worth $3,342,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GILD. Hall Laurie J Trustee boosted its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. boosted its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Penserra Capital Management LLC boosted its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Finally, Webster Bank N. A. boosted its stake in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the period. Institutional investors and hedge funds own 74.04% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.88% during midday trading on Tuesday, reaching $75.35. 6,084,547 shares of the company traded hands. The company has a 50 day moving average price of $72.97 and a 200 day moving average price of $68.86. The company has a market capitalization of $98.40 billion, a PE ratio of 8.18 and a beta of 1.21. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.07. Gilead Sciences also was the recipient of some unusual options trading activity on Monday. Traders acquired 19,878 put options on the company. This represents an increase of 209% compared to the typical daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period last year, the firm posted $3.08 EPS. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. On average, analysts expect that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.78%. Gilead Sciences’s payout ratio is currently 22.58%.

COPYRIGHT VIOLATION WARNING: “Clear Harbor Asset Management LLC Acquires 16,555 Shares of Gilead Sciences, Inc. (GILD)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/29/clear-harbor-asset-management-llc-acquires-16555-shares-of-gilead-sciences-inc-gild.html.

A number of equities research analysts have weighed in on the stock. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Robert W. Baird restated an “outperform” rating and issued a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price objective on the stock. in a report on Monday. Deutsche Bank AG restated a “buy” rating and issued a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Berenberg Bank restated a “buy” rating and issued a $86.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. Eleven equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $80.83.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock worth $15,223,184 over the last 90 days. Insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.